Laurence J. van Warmerdam

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 445 citations · Full text

Medicine, Oncology, Breast Oncology +15

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

Manon Huizing, Giuseppe Giaccone, Laurence J. van Warmerdam et al. · Journal of Clinical Oncology · 1997 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer

Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven et al. · JAMA Oncology · 2021 · 144 citations · Full text

Medicine, Oncology, Breast Oncology +15

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

Manon Huizing, Laurence J. van Warmerdam, Hilde Rosing et al. · Journal of Clinical Oncology · 1997 · 77 citations

Medicine, Oncology, Pharmacology +16

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

Laurence J. van Warmerdam, W.W. ten Bokkel Huinink, Sjoerd Rodenhuis et al. · Journal of Clinical Oncology · 1995 · 69 citations

Medicine, Oncology, Pharmacology +17